JPWO2021231579A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021231579A5
JPWO2021231579A5 JP2022569265A JP2022569265A JPWO2021231579A5 JP WO2021231579 A5 JPWO2021231579 A5 JP WO2021231579A5 JP 2022569265 A JP2022569265 A JP 2022569265A JP 2022569265 A JP2022569265 A JP 2022569265A JP WO2021231579 A5 JPWO2021231579 A5 JP WO2021231579A5
Authority
JP
Japan
Prior art keywords
mir
target sequences
raav
composition according
gene product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022569265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526310A (ja
JP2023526310A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032003 external-priority patent/WO2021231579A1/en
Publication of JP2023526310A publication Critical patent/JP2023526310A/ja
Publication of JP2023526310A5 publication Critical patent/JP2023526310A5/ja
Publication of JPWO2021231579A5 publication Critical patent/JPWO2021231579A5/ja
Pending legal-status Critical Current

Links

JP2022569265A 2020-05-12 2021-05-12 導入遺伝子発現のｄｒｇ特異的低減のための組成物 Pending JP2023526310A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063023593P 2020-05-12 2020-05-12
US63/023,593 2020-05-12
US202063038488P 2020-06-12 2020-06-12
US63/038,488 2020-06-12
US202063043562P 2020-06-24 2020-06-24
US63/043,562 2020-06-24
US202063079299P 2020-09-16 2020-09-16
US63/079,299 2020-09-16
US202163152042P 2021-02-22 2021-02-22
US63/152,042 2021-02-22
PCT/US2021/032003 WO2021231579A1 (en) 2020-05-12 2021-05-12 Compositions for drg-specific reduction of transgene expression

Publications (3)

Publication Number Publication Date
JP2023526310A JP2023526310A (ja) 2023-06-21
JP2023526310A5 JP2023526310A5 (https=) 2024-05-22
JPWO2021231579A5 true JPWO2021231579A5 (https=) 2024-05-22

Family

ID=76532231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569265A Pending JP2023526310A (ja) 2020-05-12 2021-05-12 導入遺伝子発現のｄｒｇ特異的低減のための組成物

Country Status (12)

Country Link
US (1) US20230304034A1 (https=)
EP (1) EP4162059A1 (https=)
JP (1) JP2023526310A (https=)
KR (1) KR20230010670A (https=)
CN (1) CN115803064A (https=)
AU (1) AU2021270447A1 (https=)
BR (1) BR112022022212A2 (https=)
CA (1) CA3177407A1 (https=)
CO (1) CO2022017959A2 (https=)
IL (1) IL298138A (https=)
MX (1) MX2022014258A (https=)
WO (1) WO2021231579A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR125406A1 (es) 2021-04-23 2023-07-12 Univ Pennsylvania Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
EP4409010A1 (en) 2021-10-02 2024-08-07 The Trustees of The University of Pennsylvania Novel aav capsids and compositions containing same
AR128239A1 (es) 2022-01-10 2024-04-10 Univ Pennsylvania Composiciones y métodos útiles para el tratamiento de trastornos mediados por c9orf72
JP2025512969A (ja) 2022-04-06 2025-04-22 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｈｅｒ２陽性転移性乳がん及び他のがんを治療するための組成物及び方法
US20250250326A1 (en) 2022-04-06 2025-08-07 The Trustees Of The University Of Pennsylvania Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
MA71383A (fr) * 2022-07-08 2025-04-30 Sensorion Séquences régulatrices comprenant des sites cibles de micro-arn
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
AR133098A1 (es) 2023-06-29 2025-08-27 Univ Pennsylvania Aav mutante con motivos dirigidos al sistema nervioso central y composiciones que lo contienen
IL326390A (en) 2023-08-10 2026-04-01 Univ Pennsylvania Compositions and methods for treating spinal muscular atrophy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
PL2002003T3 (pl) * 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
US20070027438A1 (en) 2005-07-26 2007-02-01 Frieder Loesel System and method for compensating a corneal dissection
CA2891996A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
EP2215223B1 (en) 2007-10-31 2013-05-01 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
DK3211075T3 (en) 2008-07-14 2019-01-21 Prec Biosciences Inc RECOGNITION SEQUENCES FOR I-CREI-DERIVED MECHANUCLEASES AND APPLICATIONS THEREOF
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2826860B1 (en) 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
EA037448B1 (ru) 2012-06-08 2021-03-30 Этрис Гмбх Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
WO2014125647A1 (ja) 2013-02-18 2014-08-21 富士通オプティカルコンポーネンツ株式会社 光受信装置
SI2984166T1 (sl) 2013-03-15 2020-09-30 The Trustees Of The University Of Pennsylvania Sestavki za zdravljenje MPSI
FR3004463A1 (fr) * 2013-04-11 2014-10-17 Genethon Systeme d'expression pour une therapie genique selective
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
RS60902B1 (sr) 2014-03-09 2020-11-30 Univ Pennsylvania Kompozicije korisne u lečenju nedostatka ornitinske transkarbamilaze (otc)
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
ES2876409T3 (es) 2014-04-25 2021-11-12 Univ Pennsylvania Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol
BR112017005892A2 (pt) 2014-09-24 2017-12-12 Hope City variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
HK1257801A1 (zh) 2015-10-28 2019-11-01 宾夕法尼亚州大学信托人 用於基因治疗的腺伴随病毒载体的鞘内给药
EP3387138B1 (en) 2015-12-11 2022-01-26 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
BR112018011975A2 (pt) 2015-12-14 2018-12-11 Univ Pennsylvania composições úteis no tratamento de atrofia muscular espinhal
CA3007330A1 (en) 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Composition for treatment of crigler-najjar syndrome
US20180363000A1 (en) 2015-12-14 2018-12-20 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
EP3411488A1 (en) 2016-02-03 2018-12-12 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
IL305449B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
KR102450833B1 (ko) 2016-04-15 2022-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 혈우병 a 치료용 유전자 요법
EP3442597A1 (en) 2016-04-15 2019-02-20 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia b
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
EP3612205B9 (en) 2017-04-21 2023-10-04 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the pcsk9 gene
KR102719222B1 (ko) 2017-05-11 2024-10-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 신경 세로이드 지질갈색소증에 대한 유전자 요법
US11680275B2 (en) * 2017-06-06 2023-06-20 University Of Massachusetts Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome
KR20200104864A (ko) 2017-11-30 2020-09-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 뮤코다당류증 iiib형에 대한 유전자 요법
KR102823833B1 (ko) 2017-11-30 2025-06-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 뮤코다당류증 iiia형에 대한 유전자 요법
WO2020132455A1 (en) * 2018-12-21 2020-06-25 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
CA3133889A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of rett syndrome
BR112021021908A2 (pt) * 2019-05-03 2022-02-01 Univ Pennsylvania Composições úteis no tratamento da leucodistrofia metacromática
WO2021081217A1 (en) * 2019-10-23 2021-04-29 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression

Similar Documents

Publication Publication Date Title
JPWO2020132455A5 (https=)
US12516352B2 (en) AAV capsids and compositions containing same
KR102526711B1 (ko) 고효율 게놈 편집을 위한 아데노-관련 바이러스 벡터 변이체 및 이의 방법
Gardlík et al. Vectors and delivery systems in gene therapy
CA2904156C (en) Vectors comprising stuffer/filler polynucleotide sequences and methods of use
US10413598B2 (en) Factor IX gene therapy
Tal Adeno-associated virus-based vectors in gene therapy
JPWO2021231579A5 (https=)
WO2020210705A1 (en) Aav-cas13d vectors and uses thereof
JPWO2020223362A5 (https=)
AU2016273577B2 (en) Poxvirus-derived promoter, and vector comprising same
JPWO2020223356A5 (https=)
WO1999061034A1 (en) Improved vectors
Snyder et al. Viral vector-mediated gene transfer for CNS disease
WO2021230385A1 (en) Method for treating muscular dystrophy by targeting utrophin gene
JPWO2021081217A5 (https=)
CN112041437A (zh) 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
JPWO2020219766A5 (https=)
JPWO2021092513A5 (https=)
Bosch et al. Gene therapy approaches in central nervous system regenerative medicine
RU2801848C1 (ru) Генетическая конструкция, адаптированная для доставки гена SMN1 человека с помощью аденоассоциированного вируса серотипа 2 для обеспечения нейроспецифичной экспрессии
US20230374483A1 (en) Modified hexosaminidase and uses thereof
Deficient 33. Molecular Characterization of Double-Stranded AAV Vector in Murine Liver
Li et al. 110. Mechanistic Study of Recombinant Adeno-Associated Virus (AAV) DNA End-Joining
JPWO2023086928A5 (https=)